SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: jz who wrote (3568)6/18/1998 7:30:00 PM
From: LR  Read Replies (1) | Respond to of 9523
 
At least 18% growth expected in earnings.

Desai added there was some expectation Pfizer's second quarter earnings, to be announced next month, will be higher than the mid-teen year-on-year percentage growth some analysts had projected in recent months amid a lack of earnings guidance from Pfizer.

"I expect at least 18 percent growth," Desai said.

Gotta love that on top of $2.1 billion.



To: jz who wrote (3568)6/18/1998 10:10:00 PM
From: Marshall Teitelbaum  Respond to of 9523
 
Actually, with newspapers around the country having articles about celebra/cox 2-inhibitors in them this am, I would doubt that the Schneider deal was all that was involved in today's movement. Spoke of potential being better than viagra. Throw in the good news a few days ago of phase IIb inhaled insulin trial for INHL, and PFE has gotten some good press lately. Of course, Schneider and likely good qtrly. earnings don't hurt any either.

Regards,

Marshall


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News